Traditional Chinese medicine for treating premature ovarian failure

Abstract

The invention discloses a traditional Chinese medicine for treating premature ovarian failure. The traditional Chinese medicine is prepared from Coelogyne occultata, gold Sophora japonica L, securinine, sharptooth incarvillea rhizome and herb, Ainsliaea pertyoides, araliae cordatae, levant cotton roots, Stellaria yunnanensis, Thesium chinense, roots of Woolly Lespedeza, Physochlaina macrophylla, Triplostegia glandulifera Wall.ex DC., cowpea, Cynanchum mooreanum Hemsl., korean pine seeds, pyrola, adhesive rehmannia dried roots, Polygonum chinense L. and ploygonatum cirrhifolium rhizomes. Pure natural traditional herbal medicines are adopted as raw materials, both symptoms and root causes are treated, the curative effect is definite, no toxic or side effect is caused, and the premature ovarian failure is not likely to reappear.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine for treating premature ovarian failure. Background technique [0002] Premature ovarian failure refers to the phenomenon of amenorrhea before the age of 40 caused by ovarian failure. It is characterized by primary or secondary amenorrhea accompanied by elevated blood gonadotropin levels and decreased estrogen levels, accompanied by a series of low estrogen symptoms such as hot flashes, hyperhidrosis, facial flushing, and low libido. Concomitant manifestations of autoimmune diseases such as thyroid disease, diabetes, lupus erythematosus, rheumatoid arthritis, vitiligo, and Crohn's disease. There are also hidden symptoms of adrenal insufficiency, such as recent weight loss, decreased appetite, unspecified abdominal pain, weakness, increased skin pigmentation, and salt addiction. [0003] Estrogen-progesterone replacement therapy is very ...

AI Technical Summary

Problems solved by technology

However, long-term HRT also has certain risks, such as the occurrence of endometrial cancer and breast cancer, but studies have shown that estrogen-progestin replacement therapy with progesterone application for more than 10 days per month can reduce the risk of endometrial cancer to almost zero. While the risk of breast cancer increased slightly, but the mortality rate did not increase